Wu et al. demonstrated that aggressive prostate cancers had increased MAO-A expression, and not MAO-B, and that knockdown of MAO-A reduced tumor growth and metastasis in vivo through HIF-1α and epithelial-to-mesenchymal transition inhibition [123,124]. The gene discussed is MAOA; the disease is prostate carcinoma.